2026 ICD-10-CM Diagnosis Code T46.7X5SAdverse effect of peripheral vasodilators, sequela
T46.7X5S is a billable ICD-10-CM diagnosis code for adverse effect of peripheral vasodilators, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T46.7X5S.
Present on Admission (POA)Billing
T46.7X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction to bamethan
- Adverse reaction to dihydroergocornine and/or dihydroergocristine and/or dihydroergocryptine
- Adverse reaction to smooth muscle relaxant
- Adverse reaction to tolazoline
- Adverse reaction to xanthine and/or xanthine derivative
- Alprostadil adverse reaction
- Betahistine adverse reaction
- Cyclandelate adverse reaction
- E series prostaglandin adverse reaction
- Ergot alkaloid adverse reaction
- Flosequinan adverse reaction
- Inositol adverse reaction
- Inositol nicotinate adverse reaction
- Isoxsuprine adverse reaction
- Minoxidil adverse reaction
- Moxisylyte adverse reaction
- Naftidrofuryl adverse reaction
- Nicofuranose adverse reaction
- Nicotinic acid adverse reaction
- Nicotinyl alcohol adverse reaction
- Pentoxifylline adverse reaction
- Phenoxybenzamine adverse reaction
- Phentolamine adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Alprostadil
a potent vasodilator agent that increases peripheral blood flow.Bencyclane
a vasodilator agent found to be effective in a variety of peripheral circulation disorders. it has various other potentially useful pharmacological effects. its mechanism may involve block of calcium channels.Betahistine
a histamine analog and h1 receptor agonist that serves as a vasodilator. it is used in meniere disease and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.Cyclandelate
a direct-acting smooth muscle relaxant used to dilate blood vessels.Dihydroergocornine
a 9,10alpha-dihydro derivative of ergotamine that contains isopropyl sidechains at the 2' and 5' positions of the molecule.Dihydroergotoxine
a mixture of three different hydrogenated derivatives of ergotamine: dihydroergocornine; dihydroergocristine; and dihydroergocryptine. dihydroergotoxine has been proposed to be a neuroprotective agent and a nootropic agent. the mechanism of its therapeutic actions is not clear, but it can act as an alpha-adrenergic antagonist and a dopamine agonist. the methanesulfonate salts of this mixture of alkaloids are called ergoloid mesylates.Ergoloid Mesylates
a mixture of the mesylates (methane sulfonates) of dihydroergocornine; dihydroergocristine; and the alpha- and beta-isomers of dihydroergocryptine. the substance produces a generalized peripheral vasodilation and a fall in arterial pressure and has been used to treat symptoms of mild to moderate impairment of mental function in the elderly.Flunarizine
flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine h1 blocking activity. it is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.Iloprost
a stable analog of epoprostenol that is a platelet aggregation inhibitor; vasodilator, and has cytoprotective properties.Isoxsuprine
a beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. it is used in the treatment of peripheral vascular disease and in premature labor.Minoxidil
a potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. (from martindale, the extra pharmacopoeia, 30th ed, p371)Moxisylyte
an alpha-adrenergic blocking agent that is used in raynaud's disease. it is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (from martindale, the extra pharmacopoeia, 30th ed, p1312)Niacin
a water-soluble vitamin of the b complex occurring in various animal and plant tissues. it is required by the body for the formation of coenzymes nad and nadp. it has pellagra-curative, vasodilating, and antilipemic properties.Niacinamide
an important compound functioning as a component of the coenzyme nad. its primary significance is in the prevention and/or cure of blacktongue and pellagra. most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.Xanthinol Niacinate
a vasodilator used in peripheral vascular disorders and insufficiency. it may cause gastric discomfort and hypotension.Nicergoline
an ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. it may ameliorate cognitive deficits in cerebrovascular disorders.Nicotinyl Alcohol
alcohol analog of nicotinic acid which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. it is used in vasospasm and threatened gangrene.Nylidrin
a beta-adrenergic agonist. nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. it is used in the treatment of peripheral vascular disorders and premature labor.Pentoxifylline
a methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. it improves blood flow by increasing erythrocyte and leukocyte flexibility. it also inhibits platelet aggregation. pentoxifylline modulates immunologic activity by stimulating cytokine production.Phenoxybenzamine
an alpha-adrenergic antagonist with long duration of action. it has been used to treat hypertension and as a peripheral vasodilator.Phentolamine
a nonselective alpha-adrenergic antagonist. it is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of raynaud disease and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.Suloctidil
a peripheral vasodilator that was formerly used in the management of peripheral and cerebral vascular disorders. it is hepatotoxic and fatalities have occurred. (from martindale, the extra pharmacopoeia, 30th ed, p1312)Tadalafil
a carboline derivative and phosphodiesterase 5 inhibitor that is used primarily to treat erectile dysfunction; benign prostatic hyperplasia and primary pulmonary hypertension.Tolazoline
a vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. it is used in treatment of persistent pulmonary hypertension of the newborn.Trimetazidine
a vasodilator used in angina of effort or ischemic heart disease.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T46.7X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T46.7X5SOverview
Is T46.7X5S (Adverse effect of peripheral vasodilators) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of peripheral vasodilators, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T46.7X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of peripheral vasodilators itself has resolved, not the original event.
What MS-DRG does T46.7X5S group to?
On inpatient claims, adverse effect of peripheral vasodilators, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T46.7X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of peripheral vasodilators, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T46.7X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of peripheral vasodilators, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
